FDA gives Axsome speedy review for depression drug, while other indications wait in the wings
Two years after mid-stage results first sent their stock flying, Axsome announced the FDA has accepted their application for a new depression drug and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
